These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31243632)

  • 1. Efficacy and safety of anticholinergics for children or adolescents with idiopathic overactive bladder: systematic review and meta-analysis.
    Noh JW; Lee B; Kim JH
    Int Urol Nephrol; 2019 Sep; 51(9):1459-1471. PubMed ID: 31243632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.
    Sievert KD; Chapple C; Herschorn S; Joshi M; Zhou J; Nardo C; Nitti VW
    Int J Clin Pract; 2014 Oct; 68(10):1246-56. PubMed ID: 24754838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of anticholinergics in Korean children with overactive bladder: a multicenter retrospective study.
    Park SJ; Pai KS; Kim JM; Park K; Kim KS; Song SH; Park S; Kim SO; Ryu DS; Baek M; Lee SD; Lee JW; Im YJ; Han SW; Chung JM; Cho MH; Ha TS; Cho WY; Suh HJ;
    J Korean Med Sci; 2014 Nov; 29(11):1550-4. PubMed ID: 25408588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of available therapies in the management of idiopathic overactive bladder: A systematic review of the literature].
    Moyson J; Legrand F; Vanden Bossche M; Quackels T; Roumeguère T
    Prog Urol; 2017 Mar; 27(4):203-228. PubMed ID: 28228331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study.
    Chancellor MB; Yehoshua A; Waweru C; Globe D; Cheng IN; Campbell KL; Joshi M; Pulicharam R
    Int Urol Nephrol; 2016 Jul; 48(7):1029-36. PubMed ID: 27032397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis.
    Drake MJ; Nitti VW; Ginsberg DA; Brucker BM; Hepp Z; McCool R; Glanville JM; Fleetwood K; James D; Chapple CR
    BJU Int; 2017 Nov; 120(5):611-622. PubMed ID: 28670786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
    Alloussi S; Mürtz G; Braun R; Gerhardt U; Heinrich M; Hellmis E; Horn W; Marschall-Kehrel D; Niklas K; Raabe M; Rössler T; Seibt B; Siemer S; Schultz-Lampel D; Walter H; Wiedeking B; Alloussi S; Bock P; Strugala G; Madersbacher H
    BJU Int; 2010 Aug; 106(4):550-6. PubMed ID: 20002668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis.
    Madhuvrata P; Singh M; Hasafa Z; Abdel-Fattah M
    Eur Urol; 2012 Nov; 62(5):816-30. PubMed ID: 22397851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
    Marschall-Kehrel D; Feustel C; Persson de Geeter C; Stehr M; Radmayr C; Sillén U; Strugala G
    Eur Urol; 2009 Mar; 55(3):729-36. PubMed ID: 18502028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women.
    Gittelman M; Weiss H; Seidman L
    J Urol; 2014 Apr; 191(4):1014-21. PubMed ID: 24231837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
    Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
    J Urol; 2017 Feb; 197(2S):S216-S223. PubMed ID: 28012773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
    Malone-Lee JG; Al-Buheissi S
    BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta-analysis.
    Cui Y; Zhou X; Zong H; Yan H; Zhang Y
    Neurourol Urodyn; 2015 Jun; 34(5):413-9. PubMed ID: 24676791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults.
    Roxburgh C; Cook J; Dublin N
    Cochrane Database Syst Rev; 2007 Jul; (3):CD003190. PubMed ID: 17636716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents.
    Lua LL; Pathak P; Dandolu V
    Neurourol Urodyn; 2017 Nov; 36(8):2123-2131. PubMed ID: 28467609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder.
    Oefelein MG
    Drug Saf; 2011 Sep; 34(9):733-54. PubMed ID: 21830836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome.
    Chapple CR; Abrams P; Andersson KE; Radziszewski P; Masuda T; Small M; Kuwayama T; Deacon S
    J Urol; 2014 Jan; 191(1):253-60. PubMed ID: 24018240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.